A new drug has been hailed as a “turning point in the fight against Alzheimer’s” after it was found to slow the progression of the disease.
Donanemab was found to slow “clinical decline” by up to 35%, meaning that people with disease could still go about performing day-to-day tasks including shopping, housekeeping, managing finances and taking medication.